Introduction
of the cell surface and possess seven-transmembrane domains (7TM) (Fig 3) . These receptors have been designated CX3CR1 through 6, CCR1 through 11, XCR1, and CX3CR1 based on whether they bind chemokines from the CXC, CC, C, orCX3Cchemokine subfamilies, respectively (Murphy et al., 2000) . The prototypical GPCR, rhodopsin, has only recently been characterized by X-ray crystallography (Palczewski et al., 2000) .
Activation of the chemokine receptor by binding its chemokine is followed by exchange of bound GDP for GTP in the α subunit of the G proteins. The G proteins disassociate from the receptor and activate several effector molecules downstream, which results in a cascade of signaling events within the cytoplasm of the cell (Mellado et al., 2001 ). This sequence of events results in diverse physiological processes including leukocyte migration and trafficking, leukocyte degranulation, cell differentiation, and angiogenesis or angiostasis (Luther and Cyster, 2001; Mackay, 2001; Szekanecz and Koch, 2001 ).
CCR7 and its ligands are essentially involved in homing of various subpopulations of T cells and antigen-presenting dendritic cells (DCs) to the lymph nodes. Within lymph nodes , T cells establish close physical contacts with DCs, which allow their antigen-specific activation. Although it is well established that these interactions are necessary for the optimal initiation of protective immunity, recent evidence demonstrates that the CCR7-dependent contacts of T cells and DCs are also essential for the induction of peripheral tolerance and the regulation of the immune response by CD4+CD25+ regulatory T (TReg) cells. Furthermore, a series of recent studies have shown that CCR7 is indispensable for the unperturbed thymic T-cell development and negative selection of self-reactive T cells (Förster et al., 2008) .
CCL19 and CCL21 are the only ligands for CCR7 Unlike CCL19, CCL21 has a uniquely long C-terminal tail containing 32 amino acids of which 12 are basic
amino-acid residues2 that allow avid binding to glycosaminoglycans and other molecules. This binding may be required for efficient presentation of CCL21 on the surface of endothelial cells (Gunn et al., 1998; Yoshida et al., 1998; Stein et al., 2000) and other cells (Friedman et al., 2006) . Podoplanin,a proteoglycan expressed by lymphatic endothelial cells, reticular stromal cells and other cell types might specifically present CCL21 (Kerjaschki, 2005) , and the expression of podoplanin might regulate the availability of CCL21 at these sites.
In human and mouse secondary lymphoid organs, CCL21 is produced by fibroblastic reticular cells of the T-cell rich area and, in mice also, by high endothelial venues (HEVs) (Carlsen et al., 2005) . In non-inflamed lymph nodes, fibroblastic reticular cells seem to be the only source of CCL19 production in both humans and mice (Link et al., 2007) . As human DCs can also produce CCL19, it is possible that activated DCs that are recruited into lymph nodes under inflammatory conditions may serve as an additional source of CCR7 ligands (Sallusto et al., 1999b) .
CCR7 is expressed by semi mature and mature DCs (Ohl et al., 2004) , thymocytes during defined stages of their development (Misslitz et al., 2004 ) (see later), naive B and T cells (Reif et al., 2002) , (Sallusto et al., 1999a) , TReg cells (Szanya et al., 2002) and a subpopulation of memory T cells known as central memory T (TCM) cells (Sallusto et al., 1999a) . CCR7 is also expressed by different non-immune cells, most notably in various malignancies.
CXCR4 is a chemokine receptor for SDF-1 chemokine, which CXCR4 is its only receptor (Horuk, 2001 ). This fact already suggests that the SDF-1-CXCR4 axis may play an important and unique biological role.
The role of the SDF-1-CXCR4 axis was extensively investigated initially for hemato/lymphopoietic cells. Accordingly, it had been demonstrated that SDF-1 regulates trafficking of CD34+ hematopoietic stem/ progenitor cells, pre-B-and T lymphocytes (Ma et al., 1998) . However, in recent years, evidence has accumulated that functional CXCR4 is also expressed on the surface of several tissue committed stem/progenitor cells. Accordingly, in addition to hematopoietic stem cells (Rosu-Myles et al., 2000) .
CXCR4 was also found to be expressed on the surface of primordial germ cells (Ara et al., 2003) , skeletal muscle satellite progenitor cells (Pituch-Noworolska et al., 2002) , neural stem cells (Lazarini et al., 2003) , liver oval/stem cells (Hatch et al., 2002) and retinal pigment epithelium progenitors (Crane et al., 2000) .
Similarly, it had been reported that the specific CXCR4ligand, SDF-1, is expressed/secreted by several tissues/organs in the body. The most important sources of SDF-1 are bone marrow-, lymph node-, muscle-and lung-derived fibroblasts (Zou et al., 1998; Ratajczak et al., 2003) . SDF-1 is also secreted by liver and kidney cells and in several regions of the central nervous system (Stumm et al., 2002) .
CXCR4, CCR7 and tumor cells
Tumor cells from at least 23 different types of human cancers of epithelial, mesenchymal and hematopoietic origin express CXCR4 (Balkwill, 2004b) . Not all cancerous cells in the primary tumor are CXCR4 positive. In ovarian and non-small-cell lung cancer, for instance, only a subpopulation of cells expresses this receptor (Scotton et al., 2001; Kijima et al., 2002) .When it has been possible to study freshly isolated tumor cells -for example from leukemia and cells that have been isolated from ovarian cancer ascites -the CXCR4 receptor is functional and various signaling pathways are activated.
Activation of CXCR4 stimulates directed migration of cancer cells and increases their invasion through Matrigel and monolayers of endothelial cells, bone marrow stromal cells and fibroblasts (Koshiba et al., 2000; Libura et al., 2002; Scotton et al., 2002) . If CXCR4 is associated with metastatic activity in vivo, expression of CXCR4 and/or its receptor CCL12 might be higher in metastases compared with primary tumors. This has been reported to be the case in two different cancer types. In a comprehensive series of more than 600 prostate cancer specimens (Sun et al., 2003) , CXCR4 protein expression increased with tumor aggressiveness and levels of CXCL12 were higher in metastatic lesions than in the primary tumor. min at room temperature. After four rinses in PBS, tissues were Covered with prepared DAB substrate-chromogen solution, incubate for 10 min (DAB Prepared by adding one drop of PolyDetector DAB Chromogen per mL of PolyDetector DAB Buffer and mix.) tissues rinsed with 5 changes of PBS, tissues Counterstained and then dehydrated . then tissues coversliped.
Evaluation of Immunostaining
All counts were performed in four alternate microscopic high-power fields (×400) using an Nickon microscope, Germany). Immunostaining was evaluated by two authors blinded to patient outcome and other clinical findings by considering The percentage of positive tumor cells from all tumor cells.
Results

Immunohistochemical Staining Analysis of CCR7 and CXCR4 in Head and Neck SCC
Staining of the CCR7 and CXCR4 proteins were identified in the cytoplasm and cell membrane of cancer cells but were not detected in the normal oral epithelium (Figure 9,11) .
54 of the 60 cases were positive for CXCR4 protein (90 %) (Figure 8 ).six cases were completely negative (10%), In addition to primary tumors, 65 regional lymph node metastasis were positive for CXCR4 expression in the cases (84.5%), 12 cases were completely negative (15.5%).
56 of the 60 cases were positive for CCR7 protein (93.3%) (Fig 10) .Four cases were completely negative (6.7%). In addition to primary tumors,73 cases from 77 regional lymph node metastasis were positive for CCR7 expression in the cases (94.9%), 4 cases were completely negative (5.1%).
CCR7, CXCR4 IHC expression in primary tumor -Correlation between the CCR7, CXCR4 IHC expression of each one according to tumor depth in primary tumor:
By one-way ANOVA test and LSD test and we found there are no difference between CCR7, CXCR4 IHC expression of each one according to tumor depth in primary tumor Table 1 High CXCR4-expressing breast tumors also produced more extensive nodal metastasis compared with low CXCR4-expressing tumors, but there was no significant correlation with blood-borne metastasis (Kato et al., 2003) .
CCR7 has been found in breast, gastric, non-small-cell lung and esophageal squamous cancer, and chronic lymphocytic leukaemia (CLL) (Müller et al., 2001; Mashino et al., 2002) (Till et al., 2002; Ding et al., 2003; Takanami, 2003) . CCR7 expression correlates with metastatic potential and poor prognosis, and its ligand CCL21 is found at high levels in the lymph nodes that drain many cancers. Takanami et al., (2003) measured the expression of CCR7 in patients with nonsmall-cell lung cancer and found an excellent correlation between the expression of CCR7 and the ability of the cancer to spread to the lymph nodes. Shimansky et al. (Schimanski et al., 2005) reported that strong expression of CXCR4 in colorectal cancer is associated with lymphatic and distal dissemination in patients with this disease. Wang et al., (2004) found a correlation between expression of CCR7 and metastasis in squamous-cell carcinoma of head and neck cancer. Laverdiere et al., (2005) have observed an association between CXCR4 expression and metastasis/ poor prognosis in patients with osteosarcoma. Ghobrial et al., (2004) observed that CXCR4 and CCR7 expression correlates with disease progression in B cell chronic lymphocytic leukemia/small lymphocytic lymphoma.
Materials and Methods
Tissue Samples
Tissues were obtained from head and neck SCC specimens for 60 patients who underwent head and neck surgery in Department of Medical University Hospital AL-Muassah (Damascous-Syria) between 2012 and 2015.
Surgical excision for each cancer with lymph node dissection was performed
The whole sample was 60 primary tumor and 77 invased lymph node, Specimens were fixed in a 10% formaldehyde solution and embedded in paraffin for immunohistochemical analysis.
Primary cancers of the head and neck were classified according to the pathological TNM classification (Barnes, 2005) .
Immunohistochemical Staining
Immunohistochemical staining was performed using the Mouse/Rabbit PolyDetector HRP/DAB Detection System .
Tissue sections were deparafinized and rehydrated in water. tissues subjected to heated epitope retrieval using a retrieval solution in microwave for 15 minutes. Washed with 5 changes of PBS, slides Placed in Poly Detector Peroxidase Blocker for 5 min. then washed with 3 changes of PBS, then tissues were incubated with the Primary Antibody(CCR7 1/100 {abcam/England}) , (CXCR4 1/500 {abcam/England}) at room temperature for 30 min. Sections were rehydrated, washed, and tissues Covered with PolyDetector HRP Label, incubate for 45 By one-way ANOVA test we found no differences between CCR7 IHC expression in primary tumor according to number of metastatic lymph nodes , while there are difference between CXCR4 IHC expression in primary tumor according to number of metastatic lymph nodes (Table 3 ) and ( Figure 5 ).
By LSD test we found there is difference CXCR4 IHC expression in primary tumor according to between one l lymph node metastases and 3 lymph node metastases, and between 3 lymph node metastases and 5 lymph node metastases (Table 4) .
Correlation between the CCR7, CXCR4 IHC expression of each one and clinical stage in primary tumor:
By one-way ANOVA test we found difference between CCR7 , CXCR4 IHC expression in cancer samples and normal samples (Table 5 
Correlation between the CCR7, CXCR4 IHC expression of each one and histologic grade in primary tumor
By one-way ANOVA test we found difference between CCR7, CXCR4 IHC expression in cancer samples and normal samples (Table 7) and (Figure7). Then we examined LSD test and we found there is no difference between histologic grade of tumor samples according to CCR7 and CXCR4 IHC expression (Table 8) .
Correlation between the CCR7, CXCR4 IHC expression of each one in primary tumor and lymph nodes metastasis
By two independent T student test and Pearson's test we found differences between primary tumor and lymph nodes metastasis according to CCR7, CXCR4 IHC expression (Table 9 ). And there is a positive correlation between primary tumor and lymph nodes metastasis according to CCR7, CXCR4 IHC expression (Tab10).
Discussion
Tumor cells at metastatic sites express chemokine receptors in several types of carcinoma, including breast , ovary , and prostate (Table 11) their receptors are known to play important roles in the processes of leukocyte trafficking and homing, especially at sites of inflammation, infection, tissue injury, cell damage and malignant tumor growth Rossi and Zlotnik, 2000 CCR7 is a chemokine receptor, which is expressed on lymphocytes, such as T cells and dendritic cells and it plays an important role in the mediation of migration of those cells toward lymph nodes which express the CCR7 ligand, CCL21 (Förster et al., 2008) .
CXCR4, acts as a receptor specific for SDF-1 and plays roles in cell migration and proliferation.
A recent study suggests that these proteins can also regulate non-leukocyte cell functions, such as tumor cell migration (wang et al., 1998) CCR7 expression in tumor tissue specimens has recently been reported to be associated with lymph node metastases by immunohistochemical analyses in various carcinomas ( (Müller et al., 2001)) Tumor cells from at least 23 different types of human cancers of epithelial, mesenchymal and hematopoietic origin express CXCR4 (Balkwill, 2004b) .
However, there are no studies to investigate this correlation between CCR7 and CXCR4 in primary and lymph node metastases in clinical stages and histological grades.
In this study, we found that CCR7 ,CXCR4 expression was detected in HNSCC tissues, but not detected in normal oral mucosa .we explained this result that one of tumor cells strategy is mimicking the movement cells , we are agree with (Xia et al., 2015) for CCR7 at SCC in tongue and agree with (Katayama et al., 2005) and (Teng et al., 2009 ) for CXCR4.
we found there is no differences between CCR7, CXCR4 IHC expression of each one according to tumor depth in primary tumor ,and that because CCL19 chemokine is more than CCL21 in tumor stroma and the complex CCL19-CCR7 protect cancer cells against apoptosis and amplify proliferative activity Tsuzuki et al., 2006 who's results showed that the staining score of proliferating cell nuclear antigen (PCNA) in SCCs was correlated with that of CCR7, however no reference connect CCR7 with MMPs, therefor the cancerous cells spread had no relation with CCR7 expression. we agree with Oliveira-Neto et al., 2013 we disagree with Ueda et al., 2010 , Shang et al., 2009 , Ding et al., 2003 , while CXCR4-SDF1 complex has a relation with MMPs however cancer stromal macrophage's cytokines inhibit SDF1 and make its gradiant far from cancer cell therefor the cancerous cells spread had no relation with CXCR4 expression we agree with (Almofti et al., 2004) Yin and Gao, 2007,Ishikawa et al., 2006 ,and disagree with (Teng et al., 2009 ), (Ueda et al., 2010) we found no differences between CCR7 IHC expression in primary tumor according to number of metastatic lymph nodes, while there are differences between CXCR4 IHC expression in primary tumor according to number of metastatic lymph nodes: we explained that CCR7 has a correlation with lymph node metastasis from its early stage while CXCR4 has a correlation with lymph node metastasis from its late stage, we agree with Tsuzuki et al., 2006 , (Ding et al., 2003 , Shang et al., 2009 for CCR7 and with Kato et al., 2003 for CXCR4. we found there is no difference between clinical stages of tumor samples according to CCR7 IHC expression, while there are difference between clinical stage 1 and 4 of tumor samples according to CXCR4 IHC expression so we can predict CCR7 expression in primary tumor as a diagnostic and prognostic factor, and we can predict CXCR4 as a prognostic factor ,we agree with (Oliveira-Neto et al., 2013) for CCR7 and with (Uchida et al., 2003; Almofti et al., 2004; Ishikawa et al., 2006; Yin and Gao, 2007; Oliveira-Neto et al., 2008 ) (Delilbasi et al., 2004 Albert et al., 2012) (Zhang et al., 2005; Tan et al., 2008) for CXCR4.
we found there is no difference between histologic grade of tumor samples according to CCR7 and CXCR4 IHC expression , that because CCR4, CXCR4 have no relation with cancer cells differentiation ,we agree with Ding et al., 2003 , Ishida et al., 2009 and disagree with (Ueda et al., 2010) , (Xia et al., 2015) for CCR7 and agree with (Katayama et al., 2005) , Ishikawa et al., 2006, Yin and Gao, 2007 we agree with (Kijowski et al., 2001; Shen et al., 2001 ) that CXCR4 increase the ability of cells which express to cell adhesion by controlling many surface integrines, we agree with (Katayama et al., 2005) who found that Exogenous SDF-1 promoted cell migration as well as proliferation in a dose dependent manner in CXCR4-positive cells but never in CXCR4-negative cells. His results showed that CXCR4 plays a role in cell Table 11 . Examples of Chemokines Receptors in Cancers proliferation in response to SDF-1.These contradictory findings suggest that cell proliferation role for CXCR4 may vary in tumor types and/or sites ,he found strong SDF-1 expressions in stromal tissues surrounding CXCR4-expressing cancer nests in metastatic lymph nodes but hardly detected SDF-1 expression in stromal tissues surrounding primary cancer nests. In conclusion the high expression of CCR7 in the cancer cells was clearly associated with early lymph node metastases expression of CXCR4 involved in cell migration at late lymph node metastasis in HNSCC.
Our results may provide an insight into future therapeutic agent that inhibits tumor metastasis and progression via down-regulating CXCR4 and CCR7 expression in patients with HNSCC.
